Lisa Rathman
Critical Care Medicine · Lancaster, PANPI 1295717957
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Boehringer Ingelheim at 25.3% of the total. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $380.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$22K
- Lilly USA, LLC$12K
- Abbott$10K
- Eli Lilly$8K
- Cvrx, Inc.$7K
- Impulse Dynamics (USA) Inc.$5K
- plus $22K from 15 others
Across 15 payments — averaging $1993.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30K
What the payments were for
- Consulting fees$36,51143%
- Speaking & faculty fees$32,63538%
- Travel & lodging$10,44612%
- Food & beverage$5,9667%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 57 | $21,665 |
| Lilly USA, LLC | 27 | $11,906 |
| Abbott | 36 | $10,283 |
| Eli Lilly | 12 | $7,946 |
| Cvrx, Inc. | 10 | $6,515 |
| Impulse Dynamics (USA) Inc. | 9 | $5,258 |
| Boston Scientific | 11 | $4,265 |
| Novo Nordisk | 6 | $4,219 |
| Merck | 12 | $3,716 |
| Medtronic | 7 | $3,287 |
| Abiomed | 5 | $3,276 |
| Novartis | 15 | $1,425 |
| Alnylam Pharmaceuticals Inc. | 4 | $970 |
| Pfizer | 4 | $200 |
| Actelion Pharmaceuticals US, Inc. | 1 | $146 |
| United Therapeutics Corporation | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| AstraZeneca | 3 | $96 |
| E.r. Squibb & Sons, L.L.C. | 2 | $86 |
| Johnson & Johnson | 1 | $50 |
| Scpharmaceuticals Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$34,133
- OPTIMIZER$6,677
- Barostim Neo System$6,352
- CARDIOMEMS$4,804
- Impella$3,144
- CardioMEMS HF System$2,600
- HeartMate 3 Left Ventricular Assist Device$2,200
- OPTIMIZER SMART SYSTEM$1,750
- GENERAL - THERAPIES$1,450
- GENERAL - STRUCTURAL HEART$1,400
- AMVUTTRA$845
- VERQUVO$392
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$265
- UPTRAVI$146
- OPSUMIT$146
- Legacy$112
- ONPATTRO$108
- LifeVest$100
How this compares
$85,558 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 45 | $951,942 |
| EliquisApixaban | 60 | $62,433 |
| JardianceEmpagliflozin | 61 | $56,526 |
| EntrestoSacubitril/Valsartan | 38 | $44,924 |
| FarxigaDapagliflozin Propanediol | 24 | $24,827 |
| XareltoRivaroxaban | 20 | $15,100 |
| Torsemide | 90 | $2,373 |
| Potassium Chloride | 29 | $1,986 |
| Metoprolol Succinate | 120 | $1,424 |
| Atorvastatin Calcium | 97 | $1,008 |
| Spironolactone | 114 | $859 |
| Bumetanide | 17 | $846 |
| Rosuvastatin Calcium | 37 | $638 |
| Ezetimibe | 26 | $506 |
| Furosemide | 112 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $200 | $1,014,375105 claims |
| Boehringer IngelheimJardiance | $21,665 | $56,52661 claims |
| NovartisEntresto | $1,425 | $44,92438 claims |
| AstraZenecaFarxiga | $96 | $24,82724 claims |
| Johnson & JohnsonXarelto | $50 | $15,10020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Lancaster
- Jill SchaefferLancaster$4K
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Robert KruklitisAllentown$148K
- Kees PoldermanPittsburgh$85K
- Pavan ThanguduHarrisburg$78K
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Michael RisbanoPittsburgh$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.